Kontinuerliga blodsockermätare, CGM, är utvecklade för personer med typ 1-diabetes som behöver veta sina värden för att anpassa insulinbehandlingen. De används även av personer med typ 2-diabetes men har också börjat säljas till personer utan diabetes, och marknadsförs ibland som ett sätt att optimera hälsan.
Men en översikt gjord av bland annat forskare vid Göteborgs universitet visar att det saknas vetenskapligt stöd för att CGM leder till bättre hälsa eller förebygger sjukdom hos personer utan diabetes.
Forskarna varnar i stället för att normala variationer i blodsockret riskerar att övertolkas och leda till oro.
Från TT
_______
Läs mer i tidskriften JAMA open source free
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2851941?guestAccessKey=193b34fb-b789-4d6f-86c6-d7471d17e406&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=080326
Review JAMA
Less Is More
Continuous Glucose Monitoring in Type 2 Diabetes and Beyond A Review
Justin A. Dower, MD1; Minna Johansson, MD, PhD2,3; Anne W. Camp, MD4
Published Online: August 3, 2026
doi: 10.1001/jamainternmed.2026.2772
Abstract
Importance Continuous glucose monitoring (CGM), initially recommended primarily for people with type 1 diabetes, has rapidly expanded to patients with type 2 diabetes and, more recently, even to individuals without diabetes. This broadening use underscores the importance of critically examining the evidence supporting CGM across populations, clarifying where benefits are established, where they are modest, and where they remain uncertain.
Observations
We reviewed systematic reviews and meta-analyses of randomized trials and clinical guidelines evaluating CGM use beyond type 1 diabetes, with particular attention to glycemic outcomes, hypoglycemia, patient-reported outcomes, and potential unintended consequences in nonpregnant adults. In adults with type 2 diabetes, evidence from randomized trials consistently demonstrated that CGM use was associated, on average, with a modest yet consistent reduction in hemoglobin A1c of approximately 0.3% compared with finger-stick monitoring or usual care; some patients benefited considerably more. Only limited and indirect evidence supported the adoption of CGM in people with type 2 diabetes not receiving glucose-lowering therapy or in those with prediabetes or obesity.
Conclusions and Relevance
CGM should be deployed in response to a specific patient problem rather than as a default intervention. Deliberate, equitable deployment of CGM that is aligned with patient goals, clinical context, and system capacity will be necessary to ensure that those most likely to benefit are not left behind, while avoiding overuse in populations for whom benefit remains unproven.
Introduction
Continuous glucose monitoring (CGM) measures interstitial glucose levels in near real time. Since the first US Food and Drug Administration approval in 1999, both the technology and the evidence supporting its use have evolved.1 Initially available only as a supplemental tool to finger-stick glucose monitoring for select patients with type 1 diabetes,2 CGM is now recommended by several authorities worldwide for all patients with type 1 diabetes and for many with type 2 diabetes receiving insulin or other therapies that pose a risk of hypoglycemia3 -5; some guidelines also suggest CGM alongside coaching for people with prediabetes.3 In 2024, the US Food and Drug Administration approved an over-the-counter CGM system,6 widening consumer access. The most commonly used modality is real-time CGM (Figure).7-10 This review examines the evidence for CGM use beyond type 1 diabetes or pregnancy, explores its usefulness as a behavior change aid, and critically assesses its expanding role in the care of people with dysglycemia.
Läs hela artikeln
Läs mer i tidskriften JAMA open source free
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2851941?guestAccessKey=193b34fb-b789-4d6f-86c6-d7471d17e406&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=080326
Nyhetsinfo
www red DiabetologNytt